Author’s response to reviews

Title: A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report

Authors:

Arie Verschoor (a.j.verschoor@lumc.nl)
Fabienne Warmerdam (f.warmerdam@zuyderland.nl)
Tjalling Bosse (T.Bosse@lumc.nl)
Judith Bovée (J.V.M.G.Bovee@lumc.nl)
Hans Gelderblom (A.J.Gelderblom@lumc.nl)

Version: 1 Date: 21 Sep 2016

Author’s response to reviews:

Dear editor,

The following comments were all addressed.

Editor's comments:

1. Please add a statement in the manuscript indicating the source of funding for this study.
   This was added to the manuscript.

2. Please rewrite the first sentence of the Introduction; this sentence overlaps with the text in another published paper.
   The first sentence was rewritten.
3. Please indicate in the manuscript ethics statement whether ethical approval was obtained and the actual name of the committee that approved the study. If study approval was not necessary, please state this in the manuscript and include a brief explanation. A statement of the subject's consent to participate in the study as well as consent for publication should also be included.

These were added.

4. Please note that all manuscripts must contain all the following sections under the heading 'Declarations':

Ethics approval and consent to participate
Consent for publication
Availability of data and material
Competing interests
Funding
Authors' contributions
Acknowledgements
Authors' information (optional)

If not present, these were added.

Best regards,

Arjan Verschoor